Notice of Correction to NOT-DA-15-052 "Request for Information (RFI): Availability of Data and Biological Specimens from NIH-funded Studies of HIV and Non-HIV-Infected Injection Drug Users for Genetic and Epigenetic Analyses"

Notice Number: NOT-DA-15-055

Key Dates
Release Date: March 19, 2015
Response Date: April 10, 2015

Related Announcements
NOT-DA-15-052

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to correct information on the title and purpose for NOT-DA-15-052 "Request for Information (RFI): Availability of Data and Biological Specimens from NIH-funded Studies of HIV and Non-HIV-Infected Injection Drug Users for Genetic and Epigenetic Analyses" which was published on March 11, 2015.

The title current reads:
Request for Information (RFI): Availability of Data and Biological Specimens from NIH-funded Studies of HIV and Non-HIV-Infected Injection Drug Users for Genetic and Epigenetic Analyses

The title is modified to read:
Request for Information (RFI): Availability of Data and Biological Specimens from Studies of HIV and Non-Infected Injection Drug Users for Genetic and Epigenetic Analysis

The Purpose currently reads:
The National Institute on Drug Abuse (NIDA) seeks information about the availability of data from biological specimens (such as blood, plasma, isolated cells [PBMCs]) obtained from HIV Infected and non-infected injection drug using (IDU) subjects used in NIH-funded clinical studies. This information will be used to determine the feasibility of developing programs for conducting genetic and epigenetic analyses of data on the host-response to HIV and modalities of personalized (precision) medicine for treating HIV infection in IDUs.

The Purpose is modified to read:
The National Institute on Drug Abuse (NIDA) seeks information about the availability of data and biological specimens (such as blood, plasma, isolated cells [PBMCs]) obtained from HIV Infected and non-infected injection drug using (IDU) subjects from studies not funded by NIH and those funded by NIH. This information will be used to determine the feasibility of developing programs for conducting genetic and epigenetic analyses of data on the host-response to HIV and modalities of personalized (precision) medicine for treating HIV infection in IDUs.

All other aspects of this RFI remain unchanged.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309
Email: NIDAInjectionDrugUse@mail.nih.gov